 |
SYDNEY, Aug. 7, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration (FDA) has awarded Rare Pediatric Disease Designation (RPDD) to Kazia's paxalisib (formerly GDC-0084) for the treatment of...
Everyone wants to live life with independence and dignity. For people with disabilities, achieving this often requires the right support. This is where NDIS providers play an important role. These pro...
Daily Bulletin
In the modern world, where manufacturing has become highly interconnected, the weakest components of the supply chain can only make the chain as strong as it is. One defective component might cause ...
Daily Bulletin
Australia’s vast geography and diverse consumer markets make logistics a critical part of business success. As companies scale and customer expectations rise, many turn to 3pl logistics australia to...
Daily Bulletin
